Skip to main content
Summary
Profile
Financials
Events
Ownership
Options

Company Info

Industry Biotechnology
Sector Health Technology
Employees 370
CEO Dr. Scott E. Koenig
Address 9704 Medical Center Drive , Rockville, MD 20850-3368
Phone 1.301.251.5172
Website www.macrogenics.com

MacroGenics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.

Competitors

Company Name 3 Month
%Change
1 Year
%Change
MacroGenics, Inc. -30.21% -27.10%
NovoCure Ltd. -33.81% -28.97%
Teva Pharmaceutical Industries Ltd. -12.79% -12.91%
Penumbra, Inc. -10.47% 12.85%
CureVac NV -37.55% -56.02%

Statement Summary

as of 4:00 ET PM 12/01/2021
Total Assets (MRQ) 392.2 M
Total Liabilities (MRQ) 100.7 M
Shareholders’ Equity (MRQ) 291.4 M
Total Revenue (Annual) 15.7 M
Net Income (Annual) -52.9 M

Earnings And Estimates

as of 4:00 ET PM 12/01/2021

Current Qtr EPS Estimate -0.81
Current FY EPS Estimate -3.25
Long Term EPS Growth Estimate n/a
Next Expected Earnings Date 3/1/2022

MGNX vs S&P 500

as of 12/01/2021
Relative To
S&P 500
MGNX
4 Weeks n/a n/a
12 Weeks n/a n/a
YTD n/a n/a

Earnings Surprises

as of 4:00 ET PM 12/01/2021
Fiscal Quarter Estimate Actual Surprise
09/2021 -0.71 -0.86 +21.04%
06/2021 -0.46 -0.66 +44.91%
03/2021 -0.64 -0.90 +40.99%
12/2020 -0.73 0.04 -105.49%
09/2020 -0.93 -0.66 -29.08%
06/2020 -0.92 -0.94 +2.17%
03/2020 -1.02 -0.91 -10.68%
12/2019 -1.02 -0.61 -40.29%

Financial Strength

as of 4:00 ET PM 12/01/2021
Pre-Tax Margin -337.67
Net Margin -71.00
Operating Margin -338.32
Return On Equity -50.15
Return On Assets -38.14
Inventory Turnover (TTM) 0.00
Sales Growth (MRQ) 0.79

Ratios

as of 4:00 PM ET 12/01/2021
Price/Earnings (TTM) n/a
Price/Book (MRQ) 3.49
Price/Cash Flow (TTM) 0.00
Book Value (MRQ) 4.76
Quick Ratio (MRQ) 4.80
Current Ratio (MRQ) 4.86
Total Debt/Equity (MRQ) 0.09

Short Interest

as of 10:57 AM ET 12/02/2021
% Short - 0.00%
% Remaining Float - 100.00%
Current Last Month
Short Interest Date n/a n/a
Short Interest Shares 0 0
Short Interest Ratio 0.0 0.0
M Y M Y
Total Assets 0,0.00 0,0.00
Total Liabilities 0,0.00 0,0.00
Total Equity 0,0.00 0,0.00
M Y M Y
Total Revenue 0,0.00 0,0.00
EBT Exc.
Unusual Items
0,0.00 0,0.00
Net Income 0,0.00 0,0.00
M Y M Y
Cash from
Operations
0,0.00 0,0.00
Cash from
Activities
0,0.00 0,0.00
Cash from
Fin. Activities
0,0.00 0,0.00

TOTAL ASSETS

TOTAL LIABILITIES

TOTAL EQUITY

Balance Sheet

M Y
ASSETS
Cash And Equivalents 0,0.00
Receivables 0,0.00
Inventories 0,0.00
Other Current Assets 0,0.00
Total Current Assets 0,0.00
Property, Plant & Equipment, Gross 0,0.00
Accumulated Depreciation & Depletion 0,0.00
Property, Plant & Equipment, Net 0,0.00
Intangibles 0,0.00
Other Non-Current Assets 0,0.00
Total Non-Current Assets 0,0.00
TOTAL ASSETS 0,0.00
Liabilities & Shareholder Equity
Accounts Payable 0,0.00
Short Term Debt 0,0.00
Total Current Liabilities 0,0.00
Long Term Debt 0,0.00
Deferred Income Taxes 0,0.00
Other Non-Current Liabilities 0,0.00
Minority Interest 0,0.00
Total Non-Current Liabilities 0,0.00
Preferred Stock Equity 0,0.00
Common Stock Equity 0,0.00
Common Par 0,0.00
Additional Paid In Capital 0,0.00
Cumulative Translation Adjustment 0,0.00
Retained Earnings 0,0.00
Treasury Stock 0,0.00
Other Equity Adjustments 0,0.00
Total Capitalization 0,0.00
TOTAL EQUITY 0,0.00
TOTAL LIABILITIES & STOCK EQUITY 0,0.00
Total Common Shares Outstanding 0,0.00
Preferred Shares 0,0.00
Treasury Shares 0,0.00
Basic Weighted Shares Outstanding 0,0.00
Diluted Weighted Shares Outstanding 0,0.00
Number Of Employees 0,0.00
Number Of Part-Time Employees 0,0.00

TOTAL REVENUES

EBT Excluding Unusual Items

NET INCOME

Income Statement

M Y
Sales 0,0.00
Cost Of Sales 0,0.00
Gross Operating Profit 0,0.00
Selling, General, And Administrative Expenses 0,0.00
Research & Development 0,0.00
Operating Income Before D & A (EBITDA) 0,0.00
Depreciation & Amortization 0,0.00
Interest Income 0,0.00
Other Income - Net 0,0.00
Special Income / Charges 0,0.00
Total Income Before Interest Expenses (EBIT) 0,0.00
Interest Expense 0,0.00
Pre-Tax Income 0,0.00
Income Taxes 0,0.00
Minority Interest 0,0.00
Net Income From Continuing Operations 0,0.00
Net Income From Discontinued Operations 0,0.00
Net Income From Total Operations 0,0.00
Extraordinary Income/Losses 0,0.00
Income From Cum. Effect Of Acct. Change 0,0.00
Income From Tax Loss Carryforward 0,0.00
Other Gains / Losses 0,0.00
Total Net Income 0,0.00
Normalized Income
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
0,0.00
Preferred Dividends 0,0.00
Net Income Available To Common 0,0.00
Basic EPS From Continuing Ops. 0,0.00
Basic EPS From Discontinued Ops. 0,0.00
Basic EPS From Total Operations 0,0.00
Basic EPS From Extraordinary Inc. 0,0.00
Basic EPS From Cum Effect Of Accounting Change 0,0.00
Basic EPS From Tax Loss Carryf'd. 0,0.00
Basic EPS From Other Gains (Losses) 0,0.00
Basic EPS, Total 0,0.00
Basic Normalized Net Income/Share 0,0.00
EPS From Continuing Ops. 0,0.00
EPS From Discontinued Ops 0,0.00
EPS From Total Ops. 0,0.00
EPS From Extraord. Inc. 0,0.00
EPS From Cum Effect of Accounting Change 0,0.00
EPS From Tax Loss Carfd. 0,0.00
EPS From Other Gains (L) 0,0.00
EPS, Total 0,0.00
Diluted Normalized Net Inc/Shr
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
0,0.00
Dividends Paid Per Share 0,0.00

CASH FROM OPERATIONS

CASH FROM INVESTING ACTIVITIES

CASH FROM FINANCING ACTIVITIES

Cash Flow Statement

M Y
Cash Flow From Operating Activities
Net Income (Loss) 0,0.00
Operating Gains/Losses 0,0.00
Gross Operating Profit 0,0.00
(Increase) Decrease In Receivables 0,0.00
(Increase) Decrease In Inventories 0,0.00
(Increase) Decrease In Other Current Assets 0,0.00
(Decrease) Increase In Other Current Liabilities 0,0.00
(Increase) Decrease In Other Working Capital 0,0.00
Other Non-Cash Items 0,0.00
Net Cash From Continuing Operations 0,0.00
Net Cash From Discontinued Operations 0,0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities 0,0.00
Sale Of Property, Plant & Equipment 0,0.00
Cash Used For Investing Activities
Sale Of Short-Term Investments 0,0.00
Purchases Of Property, Plant & Equipment 0,0.00
Acquisitions 0,0.00
Purchases Of Short-Term Investments 0,0.00
Other Cash From Investing Activities 0,0.00
Cash Provided by Financing Activities
Net Cash From Investing Activities 0,0.00
Issuance Of Debt 0,0.00
Cash Used For Financing Activities
Issuance Of Capital Stock 0,0.00
Repayment Of Long-Term Debt 0,0.00
Repurchase Of Capital Stock 0,0.00
Payment Of Cash Dividends 0,0.00
Other Financing Charges, Net 0,0.00
Net Cash From Financing Activities 0,0.00
Effect Of Exchange Rate Changes 0,0.00
Net Change In Cash & Cash Equivalents 0,0.00

Earnings Estimates

as of 4:00 ET PM 12/01/2021
Current Qtr
(12/2021)
Next Qtr
(03/2022)
Consensus Estimate $-0.81 $-0.74
# of Estimates 10 5
High Estimate $-0.71 $-0.68
Low Estimate $-1.00 $-0.87
Year Ago EPS $-0.04 $-0.90
Year Over Year Growth Estimate 2,081.48% -17.48%
Current Yr
(12/2021)
Next Yr
(12/2022)
Consensus Estimate $-3.25 $-2.91
# of Estimates 10 10
High Estimate $-3.12 $-1.81
Low Estimate $-3.43 $-4.06
Year Ago EPS $-2.47 $-3.25
Year Over Year Growth Estimate 31.52% -10.32%
Current Qtr
(12/2021)
Next Qtr
(03/2022)
Current Year
(12/2021)
Next Year
(12/2022)
Consensus Estimate $-0.81 $-0.74 $-3.25 $-2.91
# of Estimates 10 5 10 10
High Estimate $-0.71 $-0.68 $-3.12 $-1.81
Low Estimate $-1.00 $-0.87 $-3.43 $-4.06
Year Ago EPS $-0.04 $-0.90 $-2.47 $-3.25
Year Over Year Growth Estimate 2,081.48% -17.48% 31.52% -10.32%

Insider Information Summary

as of 11/30/2021
% Insiders - 3.20%
% Remaining Total Shares - 96.80%
Current 1 Month
Net Insider Transaction 1.00 M 800.00 K
Shares Bought 1.00 M 800.00 K
Shares Sold 0.00 0.00

Insider Activity

Transaction Date Insider/Title Transaction Type Market Value Shares Average Price Current Holdings

LATEST NEWS

Recent Articles from TheStreet

Snowflake Lead

Trading Snowflake After Rally: Let It SNOW for the Holidays?

Snowflake stock is ripping higher on earnings. Here are the must-know levels now as the bulls try to regain control.

Wall Street NYSE Lead

5 Top Stock Decliners Thursday as Stocks Post Gains

Stocks post gains Thursday even as new updates about the spread of the omicron Covid variant surface.

Five Below and Other Retail Stock Resolutions for 2019

Five Below Shares Rise on Earnings Above Expectations

Five Below's net income hit 43 cents a share in the quarter, up from 36 cents a year earlier and beating the FactSet analyst consensus of 29 cents.

Ford Starts Production of New Aluminum F-150 Pickup Truck

Ford F-150 Is Top U.S. Car Sold for 40th Straight Year, Top Truck for 45th Straight

Ford declared itself the victor for 2021 after releasing its November numbers Thursday. GM generally only releases its quarterly results.

Tesla Cyberquad for Kids Lead

Tesla Unveils All-Electric Cyberquad For Kids

Tesla is widening its electric-vehicle vision to kids, introducing the $1,900 Cyberquad.

Harley's Bikes May Look Hot, but the Company's Stock Chart Is Getting Cold

Harley-Davidson Stock Up; Bank of America Likes Pricing, New Models

'Higher new model pricing is likely in January [for Harley, along with] a mix of higher margin new model launches,' BofA said.

Kroger

5 Top Stock Gainers for Thursday: Kroger, Express, Snowflake

Kroger, Express, Snowflake, Denny's and Hilton Worldwide Holdings are five top stock gainers for Thursday.

GEO Group Lead

GEO Shares Fall as it Drops REIT Structure and Turns C Corp.

The switch to C corporation from REIT 'is expected to give GEO flexibility to allocate free cash flow toward reducing net recourse debt,' it said.

Lands' End Lands Narrower-Than-Expected Quarterly Loss

Lands' End Stock Drops as Q3 Revenue Misses Expectations

Retailer Lands' End says inventories recovered heading into the Cyber Monday week.

Glaxo, IP and PetMed Poised to Go Higher

Glaxo-Vir Antibody Drug Appears Effective vs. Omicron, Cleared by UK

GlaxoSmithKline says its antibody drug was 'deliberately designed with a mutating virus in mind.'